The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PHIO | -6.92% | -99.61% | -66.95% | -100% |
| S&P | +17.78% | +74.31% | +11.75% | +400% |
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$1.00K | 0.0% |
| Market Cap | $11.30M | 262.5% |
| Market Cap / Employee | $1.88M | 0.0% |
| Employees | 6 | 20.0% |
| Net Income | -$2,371.00K | -45.8% |
| EBITDA | -$2,533.00K | -51.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $21.03M | 290.8% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -63.90% | 30.8% |
| Return On Invested Capital | -104.41% | -1.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,079.00K | -51.5% |
| Operating Free Cash Flow | -$2,079.00K | -51.6% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.48 | 0.92 | 1.18 | 0.62 | 77.03% |
| Price to Tangible Book Value | 0.48 | 0.92 | 1.18 | 0.62 | 77.03% |
| Enterprise Value to EBITDA | 4.10 | -0.21 | -1.14 | 3.49 | 158.14% |
| Return on Equity | -76.1% | -102.2% | -107.6% | -69.9% | -39.09% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
